The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...

The ASX 200 stock had a good year on the chart but a mixed year in the business. Incitec Pivot's "transformation activities" ...

Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Walker announced earlier in the month that he was retiring from radio after 58 years due to ill health, having been previously diagnosed with idiopathic pulmonary fibrosis (IPF). After playing Johnny ...

Se og Hor reported a sighting of the royal boarding a flight from Gardermoen to London at 1pm with Marius Borg Høiby, 27, who ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics ...

Jessica Buettner shared her “Training recap 🤡😂 tweaked my back about 3 weeks ago, nothing serious but I’m annoyed at myself..." ...